Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERPARFUMS INCIPAR · Entity 4092 | Director · GlobalChief Commercial Officer | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERPARFUMS INC
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $84.64 · Expires 2031-12-30 | Direct | 800 |
Reported balance
After 2025-12-31 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2025-12-31 · Grant · Acquired 800 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $84.64 · Expires 2031-12-30 | Direct | 800 |
Reported balance
After 2025-12-31 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2025-12-31 · Grant · Acquired 800 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $84.64 · Expires 2031-12-30 | Direct | 800 |
Reported balance
After 2025-12-31 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2025-12-31 · Grant · Acquired 800 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $84.64 · Expires 2031-12-30 | Direct | 800 |
Reported balance
After 2025-12-31 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2025-12-31 · Grant · Acquired 800 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $84.64 · Expires 2031-12-30 | Direct | 800 |
Reported balance
After 2025-12-31 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2025-12-31 · Grant · Acquired 800 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.84 · Expires 2028-12-30 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,000 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.84 · Expires 2028-12-30 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,000 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.84 · Expires 2028-12-30 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,000 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.84 · Expires 2028-12-30 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,000 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.84 · Expires 2028-12-30 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,000 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $147.71 · Expires 2029-12-28 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $147.71 · Expires 2029-12-28 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $147.71 · Expires 2029-12-28 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $147.71 · Expires 2029-12-28 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $147.71 · Expires 2029-12-28 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $130.60 · Expires 2030-12-30 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $130.60 · Expires 2030-12-30 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $130.60 · Expires 2030-12-30 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $130.60 · Expires 2030-12-30 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 800 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $130.60 · Expires 2030-12-30 | Direct | 800 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 800 |
| Common StockSEC Table I · non-derivative | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 800 | $0.00 Strike: $84.64 | $0.00 |
DisclosureSEC source: 0001753926-26-000025 · form4.xml · derivative · entry 21 Bouillonnec Herve · CIK 0001990664 · Director · GlobalChief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2031-12-30 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 800 | $0.00 Strike: $84.64 | $0.00 |
DisclosureSEC source: 0001753926-26-000025 · form4.xml · derivative · entry 20 Bouillonnec Herve · CIK 0001990664 · Director · GlobalChief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2031-12-30 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 800 | $0.00 Strike: $84.64 | $0.00 |
DisclosureSEC source: 0001753926-26-000025 · form4.xml · derivative · entry 19 Bouillonnec Herve · CIK 0001990664 · Director · GlobalChief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2031-12-30 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 800 | $0.00 Strike: $84.64 | $0.00 |
DisclosureSEC source: 0001753926-26-000025 · form4.xml · derivative · entry 18 Bouillonnec Herve · CIK 0001990664 · Director · GlobalChief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2031-12-30 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 800 | $0.00 Strike: $84.64 | $0.00 |
DisclosureSEC source: 0001753926-26-000025 · form4.xml · derivative · entry 17 Bouillonnec Herve · CIK 0001990664 · Director · GlobalChief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2031-12-30 Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 300 | $0.00 Strike: $73.09 | $0.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · derivative · entry 7 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 300 | $0.00 Strike: $73.09 | $0.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · derivative · entry 6 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 300 | $0.00 Strike: $73.09 | $0.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · derivative · entry 5 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 300 | $0.00 Strike: $73.09 | $0.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · derivative · entry 4 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 300 | $0.00 Strike: $73.09 | $0.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · derivative · entry 3 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2025-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 22:19 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionCommon Stock | 1,500 | $73.09 | $109,635.00 |
DisclosureSEC source: 0001753926-25-001909 · form4.xml · nonDerivative · entry 2 Bouillonnec Herve · CIK 0001990664 · Director · Global Chief Commercial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.